Literature DB >> 8534657

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

J D Isaacs, G Hale, H Waldmann, A D Dick, R Haynes, J V Forrester, P Watson, P A Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8534657      PMCID： PMC505331          DOI： 10.1136/bjo.79.11.1054

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

Review 1.  Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis.

Authors:  J V Forrester
Journal:  Eye (Lond)       Date:  1992       Impact factor: 3.775

Review 2.  Eye-derived cytokines and the immunosuppressive intraocular microenvironment: a review.

Authors:  J W Streilein; G A Wilbanks; A Taylor; S Cousins
Journal:  Curr Eye Res       Date:  1992       Impact factor: 2.424

Review 3.  Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies.

Authors:  S P Cobbold; S Qin; L Y Leong; G Martin; H Waldmann
Journal:  Immunol Rev       Date:  1992-10       Impact factor: 12.988

4.  "Infectious" transplantation tolerance.

Authors:  S Qin; S P Cobbold; H Pope; J Elliott; D Kioussis; J Davies; H Waldmann
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

5.  Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.

Authors:  C M Lockwood; S Thiru; J D Isaacs; G Hale; H Waldmann
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

6.  The CAMPATH-1 antigen (CDw52).

Authors:  G Hale; M Q Xia; H P Tighe; M J Dyer; H Waldmann
Journal:  Tissue Antigens       Date:  1990-03

7.  Humanised monoclonal antibody therapy for rheumatoid arthritis.

Authors:  J D Isaacs; R A Watts; B L Hazleman; G Hale; M T Keogan; S P Cobbold; H Waldmann
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

8.  Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

Authors:  T Moreau; J Thorpe; D Miller; I Moseley; G Hale; H Waldmann; D Clayton; M Wing; N Scolding; A Compston
Journal:  Lancet       Date:  1994-07-30       Impact factor: 79.321
  8 in total
  18 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Penetration of engineered antibody fragments into the eye.

Authors:  M A Thiel; D J Coster; S D Standfield; H M Brereton; C Mavrangelos; H Zola; S Taylor; A Yusim; K A Williams
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 3.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 4.  Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.

Authors:  J Isaacs; A Dick
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

5.  Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.

Authors:  Mark D Willis; Trevor P Pickersgill; Neil P Robertson; Richard W J Lee; Andrew D Dick; Ester Carreño
Journal:  Int Ophthalmol       Date:  2016-10-11       Impact factor: 2.031

6.  Campath-1H therapy in refractory ocular inflammatory disease.

Authors:  A D Dick; P Meyer; T James; J V Forrester; G Hale; H Waldmann; J D Isaacs
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

7.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 8.  Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.

Authors:  R W J Lee; A D Dick
Journal:  Eye (Lond)       Date:  2011-09-30       Impact factor: 3.775

Review 9.  [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors:  C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

Review 10.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.